Company intelligence / Profile preview

Mandos Health

Ownership: Private
Development stage: Other

Overview

Mandos Health is advancing adrabetadex for the treatment of Niemann-Pick Type C, an ultra‑rare genetic disorder with no FDA-approved therapies. The company supports expanded access programs and plans further clinical development based on reanalysis of existing data.

Therapeutic areas: Rare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Patient advocacy groupscliniciansregulatorsMallinckrodt (asset transfer process)

Beyond the preview

Go deeper on Mandos Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mandos Health.